GURUFOCUS.COM » STOCK LIST » USA » NAS » Amgen Inc (NAS:AMGN) » Definitions » ROE % Adjusted to Book Value
Switch to:

Amgen (NAS:AMGN) ROE % Adjusted to Book Value

: 5.19% (As of Jun. 2023)
View and export this data going back to 1983. Start your Free Trial

Amgen's ROE % for the quarter that ended in Jun. 2023 was 90.96%. Amgen's PB Ratio for the quarter that ended in Jun. 2023 was 17.51. Amgen's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was 5.19%.


Amgen ROE % Adjusted to Book Value Historical Data

The historical data trend for Amgen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.53 4.80 5.39 3.90 3.30

Amgen Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Adjusted to Book Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.87 8.58 4.61 10.45 5.19

Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Amgen ROE % Adjusted to Book Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Amgen's ROE % Adjusted to Book Value falls into.



Amgen ROE % Adjusted to Book Value Calculation

Amgen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=126.47% / 38.31
=3.30%

Amgen's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=90.96% / 17.51
=5.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amgen ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Amgen's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (NAS:AMGN) Business Description

Amgen logo
Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Executives
Matthew C. Busch officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Michael V Drake director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller officer: SVP, Human Resources ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Rachna Khosla officer: SVP, Business Development ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Amy E Miles director
Linda H. Louie officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Nancy A. Grygiel officer: SVP & CCO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Peter H. Griffith officer: EVP & CFO ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon officer: EVP Global Commercial Ops C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
David M Reese officer: EVP, Research and Development ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Wanda M Austin director 6001 BOLLINGER CANYON ROAD, SAN RAMON CA 94583
Charles M Holley director
Lori A Johnston officer: SVP, HR C/O AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320